Tommy Tong

Tommy Tong

Auto-generated profile, based on publicly available information

Tommy Tong

San Diego Biomedical Research Institute , 3525 Johns Hopkins Court, San Diego, CA 92121

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Glycobiology
Verified
Journal Article
Closed access
PDF file
ADAlessio D’aDdabbo
Alessio D’aDdabbo
TTTommy Tong
Tommy Tong
ECEmma T Crooks
Emma T Crooks
KOKeiko Osawa
Keiko Osawa
JXJiamin Xu
Jiamin Xu
James BinleyJames Binley
James Binley
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected donors are vaccine paradigms. These bNAbs recognize envelope glycoprotein trimers that carry 75–90 oligomannose and complex-type glycans. Although bNAbs and their precursors must navigate past glycans, they usually also make some glycan contacts. Glycan-modified vaccines may therefore be useful to initiate and guide bNAb development. Here, we describe two ways to modify Env glycans for possible vaccine use: 1) using a cocktail of glycosidases (termed “NGAF3” (Neuraminidase, β-Galactosidase, N-Acetylglucosaminidase, endoglycosidase F3 (endo F3)) to deplete complex glycans to try to minimize bNAb-glycan clashes and 2) co-expressing β-1,4-galactosyltransferase 1 (B4G) and β-galactoside α-2,6 sialyltransferase 1 (ST6) during Env biosynthesis, creating bNAb-preferred glycan structures. Mass spectrometry revealed that NGAF3 removed glycan heads at 3/7 sites occupied by complex glycans. B4G overexpression resulted in hybrid glycan development whenever complex glycans were closely spaced. The glycan at position 611 in of Env’s gp41 transmembrane subunit was uniquely isolated from the effects of both endo F3 and B4G. B4G and ST6 co-expression increased hybrid and sialylated glycan abundance, reducing glycan complexity. In rabbit vaccinations, B4G + ST6 virus-like particles (VLPs) induced less frequent, weaker titer NAbs, implying that ST6-mediated increased Env charge dampens vaccine antibodies. In some cases, vaccine sera preferentially neutralized B4G + ST6-modified pseudovirus. HIV-1+ donor plasma NAbs were generally more effective against B4G + ST6 modified pseudovirus, suggesting a preference for less complex and/or α-2,6 sialylated Env trimers. Collectively, our data suggest that B4G and ST6 Env modifications are best suited for intermediate or late vaccine shots.

23 March 2021 in International Microbiology
Verified
Journal Article
Closed access
PDF file
MMMohammad Ridwane Mungroo
Mohammad Ridwane Mungroo
TTTommy Tong
Tommy Tong
Naveed Ahmed KhanNaveed Ahmed Khan
Naveed Ahmed Khan
TATengku Shahrul Anuar
Tengku Shahrul Anuar
SMSutherland K. Maciver
Sutherland K. Maciver
RSRuqaiyyah Siddiqui
Ruqaiyyah Siddiqui

1 October 2022 in The Natural Products Journal
Verified
Journal Article
Closed access
PDF file
MMMohammad Ridwane Mungroo
Mohammad Ridwane Mungroo
AAAyaz Anwar
Ayaz Anwar
ASAbolghasem Siyadatpanah
Abolghasem Siyadatpanah
RNRoghayeh Norouzi
Roghayeh Norouzi
TTTommy Tong
Tommy Tong
RSRuqaiyyah Siddiqui
Ruqaiyyah Siddiqui
Aim: Herein, we determined the anti-amoebic properties of propolis collected from different regions in Iran against Naegleria fowleri and Balamuthia mandrillaris. Background: Natural products remain a valuable source of compounds that are biologically active. Approximately one-third of well-known therapeutic drugs worldwide are derived from natural products. Objectives: Considering the use of propolis in folk medicine, here, for the first time, we evaluated anti-amoebic properties of propolis against free-living pathogenic amoebae, B. mandrillaris and N. fowleri. Methods: Propolis was collected from different regions of Iran and ethanolic extracts were prepared. Amoebicidal and cysticidal assays were accomplished to determine the effects of propolis against N. fowleri and B. mandrillaris. In vitro cytotoxicity assays were carried out to establish propolis effects on host cell damage. Finally, propolis metabolites were determined using spectrometric methods. Results: It was observed that propolis exhibited potent antiamoebic effects against trophozoites and cysts of both N. fowleri and B. mandrillaris at μg concentrations. When tested against cysts of both amoebae, only selected propolis exhibited cysticidal properties. The best activity was observed by propolis from the Kermanshah region, which depicted more than 95% amoebicidal activity and more than 60% cysticidal activity against both amoebae, respectively. Liquid chromatography- tandem mass spectrometry revealed that each extract is comprised of various components. Conclusion: For the first time, we showed that propolis has amoebicidal activity against both amoebae tested. Investigation into the individual activity of the components of propolis extracts and their mechanism of action against the aforementioned parasites might lead to the discovery of novel anti-amoebic compounds.

4 February 2022 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
QNQi Ron Ng
Qi Ron Ng
KTKok Keng Tee
Kok Keng Tee
James BinleyJames Binley
James Binley
TTTommy Tong
Tommy Tong
Human immunodeficiency virus type-1 (HIV-1) antigenic variation poses a great challenge for vaccine immunogen design to elicit broadly neutralizing antibodies (bNAbs). Over the last 10–15 years, great progress has been made to understand the conserved sites of sensitivity on HIV envelope glycoprotein spikes targeted by bNAbs. Plasma neutralization mapping and monoclonal antibody isolation efforts have revealed five major conserved epitope clusters. Most of this work has focused on subtype B and C-infected Caucasian or African donors. It is not clear if the same epitopes and epitope rank order preferences are also true in donors infected with different HIV-1 subtypes and with different racial backgrounds. To investigate this point, in this study we report the first attempt to profile the bNAb specificities of CRF01_AE-infected Malaysian plasmas. We first measured neutralization titers of 21 plasmas against a subtype A, B, and AE pseudovirus panel. This revealed that 14% (3 of 21) plasmas had cross-clade breadth. Focusing on the cross-neutralizing plasma P9, we used AE and JR-FL mutant pseudoviruses, gp120 monomer interference, and native polyacrylamide gel electrophoresis to better understand the neutralization specificity. P9 demonstrates CD4-binding-site specificity with trimer dependence and D368 independence.